Aura Biosciences (AURA) Income from Non-Controlling Interests (2022 - 2026)
Aura Biosciences (AURA) posted Income from Non-Controlling Interests of -$78000.0 for Q1 2026, down 609.09% on a QoQ basis from -$11000.0 in Q4 2025, and up 43.07% year-over-year from -$54520.4 in Q1 2025.
Aura Biosciences (AURA) Income from Non-Controlling Interests (2022 - 2026) Analysis & Trends
Aura Biosciences' Income from Non-Controlling Interests history runs 5 years deep, the most recent figure standing at -$78000.0 for Q1 2026.
- Quarterly Income from Non-Controlling Interests rose 43.07% year-over-year to -$78000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$120000.0 (down 206.19% YoY) and the FY2025 annual result came in at -$179000.0, up 33.95% from the prior year.
- Income from Non-Controlling Interests was -$78000.0 for Q1 2026 at Aura Biosciences, down from -$11000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $790000.0 in Q3 2024 and bottomed at -$521000.0 in Q1 2024.
- A 5-year average of $647.06 and a median of -$19000.0 in 2022 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2023 — Income from Non-Controlling Interests soared 797.33% — and 2024, when it sank 2029.63%.
- Aura Biosciences' Income from Non-Controlling Interests stood at $75000.0 in 2022, then surged by 797.33% to $673000.0 in 2023, then plunged by 150.37% to -$339000.0 in 2024, then soared by 96.76% to -$11000.0 in 2025, then plunged by 609.09% to -$78000.0 in 2026.
- Business Quant data shows AURA's Income from Non-Controlling Interests at -$78000.0 in Q1 2026, -$11000.0 in Q4 2025, and $57000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Aura Biosciences | 485.62 Mn | 400.83 Mn | - | -78,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -78,000.00 |
| Dec 31, 2025 | -11,000.00 |
| Sep 30, 2025 | 57,000.00 |
| Jun 30, 2025 | -88,000.00 |
| Mar 31, 2025 | -137,000.00 |
| Dec 31, 2024 | -339,000.00 |
| Sep 30, 2024 | 790,000.00 |
| Jun 30, 2024 | -201,000.00 |
| Mar 31, 2024 | -521,000.00 |
| Dec 31, 2023 | 673,000.00 |
| Sep 30, 2023 | 89,000.00 |
| Jun 30, 2023 | -178,000.00 |
| Mar 31, 2023 | 27,000.00 |
| Dec 31, 2022 | 75,000.00 |
| Sep 30, 2022 | -19,000.00 |
| Jun 30, 2022 | -123,000.00 |
| Mar 31, 2022 | -5,000.00 |